Home Newsfeeds Stephens & Co. Maintains Equal-Weight on First Interstate BancSys, Raises Price Target to $48

Stephens & Co. Maintains Equal-Weight on First Interstate BancSys, Raises Price Target to $48

Stephens & Co. analyst Andrew Terrell maintains First Interstate BancSys (NASDAQ:FIBK) with a Equal-Weight and raises the price target from $45 to $48.

byBenzinga Newsdesk

October 31, 2022

1 minute read

Stephens & Co. analyst Andrew Terrell maintains First Interstate BancSys (NASDAQ:FIBK) with a Equal-Weight and raises the price target from $45 to $48.

Jefferies Downgrades CytomX Therapeutics to Hold, Lowers Price Target to $2

By Benzinga Newsdesk

July 7, 9:07 AM

Jefferies analyst Roger Song downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Hold and lowers the price target from $12 to $2.

CTMX

BTIG Maintains Buy on Revolve Gr, Lowers Price Target to $50

By Benzinga Newsdesk

July 21, 9:39 AM

BTIG analyst Camilo Lyon maintains Revolve Gr (NYSE:RVLV) with a Buy and lowers the price target from $66 to $50.

RVLV

Analyst Ratings

Analyst Ratings for Fennec Pharmaceuticals

By Benzinga Insights

April 6, 9:00 AM

Analysts have provided the following ratings for Fennec Pharmaceuticals (NASDAQ:FENC) within the last quarter: Bullish Somewhat Bullish Indifferent…

FENC

Houlihan Lokey Q1 EPS $1.10 Beats $0.95 Estimate, Sales $418.64M Beat $399.36M Estimate

By Benzinga Newsdesk

July 28, 5:02 PM

Houlihan Lokey (NYSE:HLI) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $0.95 by 15.79 percent. This is a 7.56 percent decrease over earnings of $1.19 per share from the same

HLI

Stephens & Co. Maintains Equal-Weight on First Interstate BancSys, Raises Price Target to $48

Related Posts

Jefferies Downgrades CytomX Therapeutics to Hold, Lowers Price Target to $2

BTIG Maintains Buy on Revolve Gr, Lowers Price Target to $50

Analyst Ratings for Fennec Pharmaceuticals

Houlihan Lokey Q1 EPS $1.10 Beats $0.95 Estimate, Sales $418.64M Beat $399.36M Estimate